Download PDF
J Neurol Surg B Skull Base 2023; 84(03): 240-247
DOI: 10.1055/s-0042-1747962
Original Article

Health Insurance Coverage and Survival Outcomes among Nasopharyngeal Carcinoma Patients: A SEER Retrospective Analysis

Ashley Diaz 
1   Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States
,
Daniel Bujnowski 
2   Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, United States
,
Haobin Chen
3   Program in Quantitative Biomedical Sciences, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire, United States
,
Keaton Pendergrast 
4   University of Minnesota Medical School – Twin Cities, Minneapolis, Minnesota, United States
,
Peleg Horowitz
5   Section of Neurosurgery, Department of Surgery, The University of Chicago, Chicago, Illinois, United States
,
Paramita Das
5   Section of Neurosurgery, Department of Surgery, The University of Chicago, Chicago, Illinois, United States
,
Christopher Roxbury
6   Section of Otolaryngology, Department of Surgery, The University of Chicago, Chicago, Illinois, United States
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Objectives Insurance coverage plays a critical role in head and neck cancer care. This retrospective study examines how insurance coverage affects nasopharyngeal carcinoma (NPC) survival in the United States using the Surveillance, Epidemiology, and End Results (SEER) program database.

Design, Setting, and Participants A total of 2,278 patients aged 20 to 64 years according to the International Classification of Diseases for Oncology (ICD-O) codes C11.0–C11.9 and ICD-O histology codes 8070–8078 and 8080–8083 between 2007 and 2016 were included and grouped into privately insured, Medicaid, and uninsured groups. Log-rank test and multivariable Cox's proportional hazard model were performed.

Main Outcome Measures Tumor stage, age, sex, race, marital status, disease stage, year of diagnosis, median household county income, and disease-specific survival outcomes including cause of death were analyzed.

Results Across all tumor stages, privately insured patients had a 59.0% lower mortality risk than uninsured patients (hazard ratio [HR]: 0.410, 95% confidence interval [CI]: [0.320, 0.526], p < 0.01). Medicaid patients were also estimated to have 19.0% lower mortality than uninsured patients (HR: 0.810, 95% CI: [0.626, 1.048], p = 0.108). Privately insured patients with regional and distant NPC had significantly better survival outcomes compared with uninsured individuals. Localized tumors did not show any association between survival and type of insurance coverage.

Conclusion Privately insured individuals had significantly better survival outcomes than uninsured or Medicaid patients, a trend that was preserved after accounting for tumor grade, demographic and clinicopathologic factors. These results underscore the difference in survival outcomes when comparing privately insured to Medicaid/uninsured populations and warrant further investigation in efforts for health care reform.

Keywords

insurance status - nasopharyngeal carcinoma - survival outcomes - insurance coverage - health insurance

Note

This work will be presented in a podium presentation at the North American Skull Base Society Annual Meeting in Phoenix, Arizona, United States on February 20, 2022.


Authors' Contribution

All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors conceptualized and designed the study. All authors helped in data acquisition and analysis and interpretation. All authors drafted the manuscript. Critical revision and final approval were done by all authors.




Publication History

Received: 05 December 2021

Accepted: 07 March 2022

Article published online:
02 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Han X, Yabroff KR, Robbins AS, Zheng Z, Jemal A. Dependent coverage and use of preventive care under the Affordable Care Act. N Engl J Med 2014; 371 (24) 2341-2342
    CrossrefPubMedGoogle Scholar
  • 2 Sun M, Cole AP, Lipsitz SL, Trinh QD. Trends in breast, colorectal, and cervical cancer incidence following the Affordable Care Act: implications for cancer screening. JAMA Oncol 2018; 4 (01) 128-129
    CrossrefPubMedGoogle Scholar
  • 3 Meyer CP, Allard CB, Sammon JD. et al. The impact of Medicare eligibility on cancer screening behaviors. Prev Med 2016; 85: 47-52
    CrossrefPubMedGoogle Scholar
  • 4 UC Bureau. Health Insurance Coverage in the United States: 2019. The United States Census Bureau; . Accessed May 23, 2021 at: https://www.census.gov/library/publications/2020/demo/p60-271.html
    Google Scholar
  • 5 Panth N, Simpson MC, Sethi RKV, Varvares MA, Osazuwa-Peters N. Insurance status, stage of presentation, and survival among female patients with head and neck cancer. Laryngoscope 2020; 130 (02) 385-391
    CrossrefPubMedGoogle Scholar
  • 6 Itamura K, Kokot N, Sinha U, Swanson M. Association of insurance type with time course of care in head and neck cancer management. Laryngoscope 2020; 130 (11) E587-E592
    CrossrefPubMedGoogle Scholar
  • 7 Grant SR, Walker GV, Guadagnolo BA, Koshy M, Allen PK, Mahmood U. Variation in insurance status by patient demographics and tumor site among nonelderly adult patients with cancer. Cancer 2015; 121 (12) 2020-2028
    CrossrefPubMedGoogle Scholar
  • 8 Markt SC, Lago-Hernandez CA, Miller RE. et al. Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer 2016; 122 (20) 3127-3135
    CrossrefPubMedGoogle Scholar
  • 9 Abdelsattar ZM, Hendren S, Wong SL. The impact of health insurance on cancer care in disadvantaged communities. Cancer 2017; 123 (07) 1219-1227
    CrossrefPubMedGoogle Scholar
  • 10 Niu X, Roche LM, Pawlish KS, Henry KA. Cancer survival disparities by health insurance status. Cancer Med 2013; 2 (03) 403-411
    CrossrefPubMedGoogle Scholar
  • 11 Cervenka BP, Rao S, Farwell DG, Bewley AF. Efficacy of laryngectomy alone for treatment of locally advanced laryngeal cancer: a stage- and subsite-specific survival analysis. Clin Otolaryngol 2018; 43 (02) 544-552
    CrossrefPubMedGoogle Scholar
  • 12 Challapalli SD, Simpson MC, Adjei Boakye E. et al. Survival differences in nasopharyngeal carcinoma among racial and ethnic minority groups in the United States: a retrospective cohort study. Clin Otolaryngol 2019; 44 (01) 14-20
    CrossrefPubMedGoogle Scholar
  • 13 Richards MK, Dahl JP, Gow K. et al. Factors associated with mortality in pediatric vs adult nasopharyngeal carcinoma. JAMA Otolaryngol Head Neck Surg 2016; 142 (03) 217-222
    CrossrefPubMedGoogle Scholar
  • 14 Nittala MR, Kanakamedala MR, Mundra E. et al. Quality-adjusted life years and disability-adjusted life years are better with concurrent chemoradiation therapy than induction chemotherapy followed by chemoradiation therapy in nasopharyngeal carcinoma. Cureus 2021; 13 (01) e13022
    PubMedGoogle Scholar
  • 15 Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17 (06) 1471-1474
    CrossrefPubMedGoogle Scholar
  • 16 Thompson LDR. Update on nasopharyngeal carcinoma. Head Neck Pathol 2007; 1 (01) 81-86
    CrossrefPubMedGoogle Scholar
  • 17 Fang FM, Tsai WL, Go SF. et al. Implications of quantitative tumor and nodal regression rates for nasopharyngeal carcinomas after 45 Gy of radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50 (04) 961-969
    CrossrefPubMedGoogle Scholar
  • 18 Tsang RK, Wei WI. Salvage surgery for nasopharyngeal cancer. World J Otorhinolaryngol Head Neck Surg 2015; 1 (01) 34-43
    CrossrefPubMedGoogle Scholar
  • 19 See A, Chu C, Kiong KL. et al. Surgical salvage of recurrent nasopharyngeal cancer- a multi-institutional review. Oral Oncol 2021; 122: 105556
    CrossrefPubMedGoogle Scholar
  • 20 Reddy SP, Raslan WF, Gooneratne S, Kathuria S, Marks JE. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol 1995; 16 (02) 103-108
    CrossrefPubMedGoogle Scholar
  • 21 Lin YH, Chang KP, Lin YS, Chang TS. Evaluation of effect of body mass index and weight loss on survival of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Radiat Oncol 2015; 10: 136
    CrossrefPubMedGoogle Scholar
  • 22 Zeng Z, Shen L, Wang Y. et al. A nomogram for predicting survival of nasopharyngeal carcinoma patients with metachronous metastasis. Medicine (Baltimore) 2016; 95 (27) e4026
    CrossrefPubMedGoogle Scholar
  • 23 Hutajulu SH, Howdon D, Taroeno-Hariadi KW. et al. Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: a hospital-based retrospective study. PLoS One 2021; 16 (02) e0246638
    CrossrefPubMedGoogle Scholar
  • 24 Wang CC, Yang CC, Yeh SA. et al. The impact of insurance and marital status on survival in patients with nasopharyngeal carcinoma. Biology (Basel) 2020; 9 (04) 84
    PubMedGoogle Scholar
  • 25 Surveillance, Epidemiology, and End Results Program. SEER. Accessed July 21, 2021 at: https://seer.cancer.gov/index.html
    PubMedGoogle Scholar
  • 26 Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999; 8 (12) 1117-1121
    PubMedGoogle Scholar
  • 27 Fritz A, Percy C, Jack A. et al. International Classification of Diseases for Oncology. World Health Organization; 2000. . Accessed September 4, 2021 at: https://apps.who.int/iris/handle/10665/42344
    Google Scholar
  • 28 Huang SJ, Tang YY, Liu HM. et al. Impact of age on survival of locoregional nasopharyngeal carcinoma: an analysis of the Surveillance, Epidemiology, and End Results program database, 2004-2013. Clin Otolaryngol 2018; 43 (05) 1209-1218
    CrossrefPubMedGoogle Scholar
  • 29 Insurance Recode Variable - SEER Documentation. SEER. Accessed September 6, 2021 at: https://seer.cancer.gov/seerstat/variables/seer/insurance-recode/index.html
    PubMedGoogle Scholar
  • 30 Summary Staging | SEER Training. Accessed July 25, 2021 at: https://training.seer.cancer.gov/staging/systems/summary/
    PubMedGoogle Scholar
  • 31 Hsu CD, Wang X, Habif Jr DV, Ma CX, Johnson KJ. Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old. Cancer 2017; 123 (16) 3125-3131
    CrossrefPubMedGoogle Scholar
  • 32 Walker GV, Grant SR, Guadagnolo BA. et al. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol 2014; 32 (28) 3118-3125
    CrossrefPubMedGoogle Scholar
  • 33 Stubbs VC, Rajasekaran K, Chen J, Cannady SB, Brant JA, Newman JG. Impact of payer status on survival in parotid malignancy. Am J Otolaryngol 2019; 40 (04) 555-559
    CrossrefPubMedGoogle Scholar
  • 34 Rohlfing ML, Mays AC, Isom S, Waltonen JD. Insurance status as a predictor of mortality in patients undergoing head and neck cancer surgery. Laryngoscope 2017; 127 (12) 2784-2789
    CrossrefPubMedGoogle Scholar
  • 35 Du E, Mazul AL, Farquhar D. et al. Long-term survival in head and neck cancer: impact of site, stage, smoking, and human papillomavirus status. Laryngoscope 2019; 129 (11) 2506-2513
    CrossrefPubMedGoogle Scholar
  • 36 Duprez F, Berwouts D, De Neve W. et al. Distant metastases in head and neck cancer. Head Neck 2017; 39 (09) 1733-1743
    CrossrefPubMedGoogle Scholar
  • 37 Slatore CG, Au DH, Gould MK. American Thoracic Society Disparities in Healthcare Group. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes. Am J Respir Crit Care Med 2010; 182 (09) 1195-1205
    CrossrefPubMedGoogle Scholar
  • 38 Zhu SH, Anderson CM, Zhuang YL, Gamst AC, Kohatsu ND. Smoking prevalence in Medicaid has been declining at a negligible rate. PLoS One 2017; 12 (05) e0178279
    CrossrefPubMedGoogle Scholar
  • 39 United States National Health Interview Survey 2014 | GHDx. Accessed January 9, 2022 at: http://ghdx.healthdata.org/record/united-states-national-health-interview-survey-2014
    PubMedGoogle Scholar
  • 40 Singh B, Golden R. The uninsured patient. Am J Med 2006; 119 (02) 166.e1-166.e5
    CrossrefPubMedGoogle Scholar
  • 41 Baker DW, Stevens CD, Brook RH. Regular source of ambulatory care and medical care utilization by patients presenting to a public hospital emergency department. JAMA 1994; 271 (24) 1909-1912
    CrossrefPubMedGoogle Scholar
  • 42 Sommers BD, Baicker K, Epstein AM. Mortality and access to care among adults after state Medicaid expansions. N Engl J Med 2012; 367 (11) 1025-1034
    CrossrefPubMedGoogle Scholar
  • 43 Polite BN, Griggs JJ, Moy B. et al. American Society of Clinical Oncology policy statement on Medicaid reform. J Clin Oncol 2014; 32 (36) 4162-4167
    CrossrefPubMedGoogle Scholar
  • 44 Liu Z, Chang ET, Liu Q. et al. Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area. Cancer 2017; 123 (14) 2716-2725
    CrossrefPubMedGoogle Scholar
  • 45 OuYang PY, Zhang LN, Lan XW. et al. The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis. Br J Cancer 2015; 112 (09) 1554-1561
    CrossrefPubMedGoogle Scholar
  • 46 Xiao G, Cao Y, Qiu X, Wang W, Wang Y. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer 2013; 13 (01) 226
    CrossrefPubMedGoogle Scholar